Atomwise Inc. patented the first deep learning technology for structure-based small molecule drug discovery. This AI technology harnesses millions of data points and thousands of protein structures to solve problems that a human chemist would take many lifetimes to solve. Atomwise has partnered with some of the world’s largest pharmaceutical and agtech companies and with…
On Wednesday, Mountain View-based accelerator Y Combinator (YC) published its list of its top 100 companies for 2019, which ranks its top startups by valuation. Canadian startups that were on...
A University of Toronto startup using artificial intelligence to speed drug discovery has raised US$45 million to fund growth – yet another example of how efforts to commercialize the university’s...
Atomwise, which operates an artificial intelligence (AI)-based drug discovery platform, has raised $163 million CAD ($123 million USD) in what it called an oversubscribed Series B financing round.
University of Toronto alumnus Abraham Heifets (PhD 2014) has spent the past seven years channeling his love of science and a desire to impact the world into Atomwise, a company...
U of T drug discovery scale-up Atomwise has established a strategic and exclusive research collaboration with Sanofi that will leverage its AtomNet® platform for computational discovery and research of up to...
Few figures have loomed larger in recent public dialogue over artificial intelligence than Geoffrey Hinton, the groundbreaking AI researcher who famously left Google Brain in May, saying he wanted to...
